BiotechTube

Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Colitis, Ulcerative

Conditions

Colitis, Ulcerative

Trial Timeline

Oct 1, 2018 → Dec 31, 2019

NCT ID
NCT03669029

About Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.

Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization. is a approved stage product being developed by Merck for Colitis, Ulcerative. The current trial status is unknown. This product is registered under clinical trial identifier NCT03669029. Target conditions include Colitis, Ulcerative.

What happened to similar drugs?

16 of 20 similar drugs in Colitis, Ulcerative were approved

Approved (16) Terminated (7) Active (4)
✅Azathioprine + PlaceboCelltrionApproved
✅Filgotinib MaleateEisaiApproved
✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved
✅AdalimumabAbbVieApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved
✅Prefilled Syringe delivery of Golimumab + Smartject Device delivery of GolimumabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03669029ApprovedUNKNOWN

Competing Products

20 competing products in Colitis, Ulcerative

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
Filgotinib MaleateEisaiApproved
50
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42